Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance.

Pharmacology & therapeutics - 1 Jun 2014

Maroun Christiane R, Rowlands Tracey

Abstract excerpt

The Met receptor tyrosine kinase (RTK) is an attractive oncology therapeutic target. Met and its ligand, HGF, play a central role in signaling pathways that are exploited during the oncogenic process, including regulation of cell proliferation, invasion, angiogenesis, and cancer stem cell regulation. Elevated Met and HGF as well as numerous Met genetic alterations have been reported in human cancers and correlate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinogenesis
Share to Biomarkers, Tumor
Share to Drug Discovery

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Gene Amplification

Share to Gene Dosage

Share to Protein Structure, Tertiary

Share to Proto-Oncogene Proteins c-met

Source

Identifiers

PMID: 24384534
DOI: 10.1016/j.pharmthera.2013.12.014

Genes

HGF
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance.PMID 24384534Read ↗

MET receptor tyrosine kinase as a therapeutic anticancer target.Semantic proximity Read ↗

Targeting mesenchymal-epithelial transition factor signaling in cancer: from genetic alterations to clinical advances and future prospects.Semantic proximity Read ↗

Targeting the c-Met Signaling Pathway in CancerSemantic proximity Read ↗

Cancer therapy: can the challenge be MET?Semantic proximity Read ↗

Targeting the hepatocyte growth factor/Met pathway in cancer.Semantic proximity Read ↗

Targeting the c-MET signaling pathway for cancer therapySemantic proximity Read ↗

Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunitiesSemantic proximity Read ↗

Targeting MET Dysregulation in CancerSemantic proximity Read ↗

The METeoric rise of MET in lung cancerSemantic proximity Read ↗

MET: a new promising biomarker in non-small-cell lung carcinoma.Semantic proximity Read ↗

Overcoming resistance to targeted therapy using MET inhibitors in solid cancers: evidence from preclinical and clinical studies.Semantic proximity Read ↗

MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.